The U.N. children’s fund, UNICEF, warns many children are likely to die from vaccine preventable diseases because of a decline in routine immunization during the COVID-19 pandemic.

New data in UNICEF’s State of the World’s Children 2023 report show a significant drop in confidence in the importance of vaccines for children in 52 out of 55 countries studied, noting that vaccination rates have declined by more than a third in South Korea, Papua New Guinea, Ghana, Senegal, and Japan. Only in three countries — China, India, and Mexico — did the data show people remained positive about the health benefits of vaccination.

In most countries, the study said, “people under 35 and women were more likely to report less confidence about vaccines for children after the start of the pandemic.”

This is particularly worrisome as the report finds 67 million children, nearly half of them on the African continent, have missed out on one or more vaccinations due to disruptions in immunization services during the three years of the COVID-19 pandemic.

Fear and disinformation

Authors of the report warn the threat of vaccine hesitancy may be growing due to factors such as misleading information about vaccine safety, declining trust in expertise, and political polarization that are discouraging parents from vaccinating their children.

“At the height of the pandemic, scientists rapidly developed vaccines that saved countless lives,” said Catherine Russell, UNICEF Executive Director. “But, despite this historic achievement, fear and disinformation about all types of vaccines circulated as widely as the virus itself.”

Gains eroded

Health agencies report four million deaths are prevented worldwide by childhood vaccinations every year. But UNICEF warns that much of the gains made over many years in routine childhood immunization have been eroded in the past three years.

“The COVID-19 pandemic was largely responsible for the backsliding in coverage, but it also exacerbated existing inequities,” said Ephrem Lemango, UNICEF’s Associate Director of Immunization.

“As a result, a total of 67 million children missed out on routine vaccination between 2019 and 2021” and 48 million did not receive a single routine vaccine, “also known as zero-dose,” he said.

The report said India and Nigeria have the largest numbers of zero-dose children but increases in the numbers of children who did not receive a single dose of DTP-containing vaccine – against diphtheria, tetanus, pertussis — are especially notable in Myanmar and the Philippines.

Lemango said “for far too many children, especially in the most marginalized communities, vaccination is still not available, accessible, or affordable.”

“The analysis in this report clearly shows, children in the poorest households, living in rural areas, and born to a mother with no education and limited empowerment are most likely to lose one or more vaccinations, and to face multiple deprivations,” he said.

On the other hand, he noted that in some countries such as Nigeria, Angola, and Ethiopia, “you will find that the wealthiest 10 percent of the households are up to 10 to 20 times more likely to have their kids vaccinated as opposed to the poorest households.”

UNICEF is calling for urgent catch-up action for those children who have missed out on vaccinations to prevent deadly disease outbreaks, noting that the number of measles cases in 2022 was more than double the total in the previous year and that 16% more children have been paralyzed by polio.

“Immunizations have saved millions of lives and protected communities from deadly disease outbreaks,” said UNICEF Dirrector Russell. “Routine immunizations and strong health systems are our best shot at preventing future pandemics, unnecessary deaths, and suffering.”

The report is urging governments to identify and reach all children, especially the 67 million who missed vaccines because of the COVID pandemic. It is calling on states to strengthen their primary health care to better support immunization services, including by providing better conditions to the female workforce.

“We are calling on the world and global community to be able to prioritize this issue and avert a child survival crisis before it happens and before it is too late,” said UNICEF’s Ephrem Lemango.
…

your ads here!

By day, Jessica Wade spends her time in a laboratory at Imperial College London surrounded by spectrometers, oscilloscopes — and men.

At night, she writes biographies on Wikipedia about women researchers like her who don’t have an online presence.

“We can’t just do the shouting about how we need more women in science. We have to do the point of honoring and celebrating the women scientists that we have,” she told AFP.

“And I think writing their stories, making sure the world recognizes what they’ve done is a really important way to do that.”

Wade, 34, has worked at Imperial’s imposing campus in west London since 2016.

As a physicist, she is involved in developing new generations of carbon-based semi-conductors to make optical and electronic devices such as televisions and solar panels more energy efficient.

She leads a team of five people in a wider team of about 15. Of them, only one other scientist is a woman.

Science “is very male dominated,” Wade said, lamenting the lack of interest in it among girls whose parents are not scientists.

“As soon as I walked into a physics department that had a majority of men and a majority of people from white privileged backgrounds, I suddenly realized that not everyone’s getting the opportunity to study physics, not everyone’s getting excited about it,” she added.

“That lack of diversity impacts the science we do, the questions we ask, the directions we go in, the way we translate our innovations into society, where those kinds of devices are actually used in the world and who they benefit.”

Visibility

Wade now seeks to “take science to more people” but came across “knowledge gaps” in the internet’s free, multilingual, collaborative encyclopedia.

“Wikipedia is an amazing platform because it’s used by everyone in society,” she said.

“It’s used by 15 billion access points a month. Parents, teachers, policymakers, journalists, scientists, Amazon, Alexa, Google Home, they all use Wikipedia when they’re looking for information.”

But there is one big problem, she added: “About 90% of Wikipedia contributors and editors are men, and about 19% of the biographies on English language Wikipedia are about women.”

Wade set out to redress the imbalance in 2018 and has since written almost 2,000 pages by herself at the rate of one a night, at home, after dinner.

“They take more than one hour each, so that’s already too many hours of my life,” she laughed.

But she is undeterred by the daunting task.

“I don’t see it stopping anytime soon,” she said.

In fact, the research itself creates more work, as she often discovers more women scientists when writing another biography.

Wades’ first Wikipedia biography entry was the American climatologist Kim Cobb.

She saw her at a conference but after looking her up on Wikipedia found there was nothing on her oceanographic research.

Acknowledgement

Wade, who is now part of a network of women editors and leads workshops on how to write for Wikipedia, says a person’s presence and their work on the internet means they are discoverable.

“Little girls who are googling something, let’s say about sea urchins, will click through and then land on a Wikipedia page about an awesome woman scientist who had contributed to that,” she said.

“If you’re trying to nominate someone for an award or to become a fellow or to invite someone to give a lecture, you always google them and if they’ve got a biography nicely summarized on somewhere like Wikipedia, it’s so much easier to write someone’s citation or reference.”

That happened for Gladys West, a 92-year-old black American mathematician, whose profile was one of Wade’s first.

Starting in 1956, when racial segregation was still imposed in the United States, she worked for 42 years on navy navigation systems. Her calculations eventually led to the development of GPS.

“I researched Gladys to write her page and there was so little about her online, she was almost 90 and no one had celebrated her,” she said.

“I put her Wikipedia page online in February 2018 and in May 2018 she was in the BBC top 100 women in the world.

“And then she was inducted to the US Air Force Hall of Fame, and she won the Royal Academy of Engineering Prince Philip medal, which had never before gone to a woman.”
…

your ads here!

At least 67 million children partially or fully missed routine vaccines globally between 2019 and 2021 because of lockdowns and health care disruptions caused by the COVID-19 pandemic, the United Nations said Wednesday.

“More than a decade of hard-earned gains in routine childhood immunization have been eroded,” read a new report from the U.N.’s children’s agency, UNICEF, adding that getting back on track “will be challenging.”

Of the 67 million children whose vaccinations were “severely disrupted,” 48 million missed routine vaccines entirely, UNICEF said, flagging concerns about potential polio and measles outbreaks.

Vaccine coverage among children declined in 112 countries and the percent of children vaccinated worldwide slipped 5 percentage points to 81%, a low not seen since 2008. Africa and South Asia were particularly hard-hit.

“Worryingly, the backsliding during the pandemic came at the end of a decade when, in broad terms, growth in childhood immunization had stagnated,” the report said.

Vaccines save 4.4 million lives each year, a number the United Nations says could jump to 5.8 million by 2030 if its ambitious targets to leave “no one behind” are met.

“Vaccines have played a really important role in allowing more children to live healthy, long lives,” Brian Keeley, the report’s editor in chief, told AFP. “Any decline at all in vaccination rates is worrying.”

Before the introduction of a vaccine in 1963, measles killed about 2.6 million people each year, mostly children. By 2021, that number had fallen to 128,000.

But between 2019 and 2021, the percentage of children vaccinated against measles fell from 86% to 81%, and the number of cases in 2022 doubled compared with 2021.

The slide in vaccination rates could be compounded by other crises, Keeley warned, from climate change to food insecurity.

“You’ve got [an] increasing number of conflicts, economic stagnation in a lot of countries, climate emergencies, and so on,” he said. “This all sort of makes it harder and harder for health systems and countries to meet vaccination needs.”

UNICEF called on governments “to double-down on their commitment to increase financing for immunization” with special attention on accelerating “catch-up” vaccination efforts for those who missed their shots.

The report also raised concerns about a drop in people’s confidence in vaccines, seen in 52 out of 55 countries surveyed.

“We cannot allow confidence in routine immunizations to become another victim of the pandemic,” Catherine Russell, UNICEF’s executive director, said in a statement. “Otherwise, the next wave of deaths could be of more children with measles, diphtheria or other preventable diseases.”

Vaccine confidence can be “volatile and time specific,” the report said, noting that “further analysis will be required to determine if the findings are indicative of a longer-term trend” beyond the pandemic.

Overall, it said that support for vaccines “remains relatively strong.”

In about half of the 55 countries surveyed, more than 80% of respondents “perceived vaccines as important for children.”

“There is reason to be somewhat hopeful that services are recovering in quite a few countries,” said Keeley, who added that preliminary vaccination data from 2022 showed encouraging signs.

But even getting numbers back up to pre-pandemic levels will take years, he said, not including reaching “the children who were missing before the pandemic.”

“And they are not an insubstantial number.”

 
…

your ads here!

Older Americans and people with weak immune systems can get an extra COVID-19 booster dose this spring.

The Centers for Disease Control and Prevention on Wednesday signed off on a more flexible booster schedule for people who remain at the highest risk from COVID-19 — giving them the choice of a second “bivalent” Pfizer or Moderna booster, the most up-to-date formula.

“Many in the population are experiencing vaccine fatigue but there is a subset who are eager to receive additional doses,” CDC’s Dr. Sara Oliver told an agency advisory panel that expressed support for the change.

The move came a day after the Food and Drug Administration took steps to make coronavirus vaccinations simpler for everyone. From now on, anyone getting a Pfizer or Moderna dose — whether it’s a booster or their first-ever vaccination — will get an updated version rather than the outdated original shots.

Here are some things to know:

Who needs a booster?

Anyone who’s gotten their original vaccinations but hasn’t had an updated booster yet can still get one. Only 42% of Americans 65 and older — and just 20% of all adults — have gotten one of those updated boosters since September.

Who can get a second updated booster?

People 65 or older who already had one Pfizer or Moderna updated booster can roll up their sleeves again, as long as it’s been at least four months since that last shot.

The schedule is a little different for people with weak immune systems. Most can choose a second Pfizer or Moderna updated booster at least two months after their first. Under the latest FDA and CDC guidelines, they also could get additional doses if and when their physician decides they need one.

Why the extra leeway?

Older adults continue to have the highest rates of hospitalization from COVID-19, even as cases have declined. But a frail 85-year-old may want another booster right away, while a robust 65-year-old may not see the need — or might instead time another shot for peak protection ahead of a summer vacation or other special event.

CDC officials stressed there’s even more variety among immune-compromised patients, from people with only mild impairment to those trying to replenish immunity that grueling cancer treatment knocked out.

The changes put the U.S. in line with Britain and Canada, which also are offering certain vulnerable populations a spring shot. It’s a reasonable choice, Dr. Matthew Laurens, of the University of Maryland School of Medicine, said before the announcement.

“We do have vaccines that are available to protect against these severe consequences, so why not use them?” he said. “They don’t do any good just sitting on a shelf.”

Will younger, healthier people get a fall dose?

Stay tuned. The FDA will hold a public meeting in June to consider if the vaccine recipe needs more adjusting to better match the latest coronavirus strains — just like it adjusts flu vaccines every year. And part of that discussion will be whether younger, healthier people also need a booster.

The updated Pfizer and Moderna shots being used now target the BA.4 and BA.5 omicron versions, which have been replaced by an ever-changing list of omicron descendants. Still, while protection against mild infections is short-lived, those updated doses continue to do a good job fighting severe disease and death even against the newest variants.

Tots are least likely to be vaccinated yet

CDC’s advisers were dismayed at how few of the youngest children are vaccinated. Just 6% of 2- to 4-year-olds have gotten their initial COVID-19 shots and 4.5% of those younger than 2. Far fewer got an updated booster.

The FDA’s new rules mean tots under 5 who’ve never been vaccinated can get the most up-to-date formula — two Moderna shots or three of the Pfizer-BioNTech version. Unvaccinated 5-year-olds can get two Moderna doses or a single Pfizer shot. And tots already fully or partially vaccinated may get a bivalent shot or two depending on their vaccination history.

What about the Novavax vaccine?

Novavax makes a more traditional type of COVID-19 vaccine, and its original formula remains available for people who don’t want the Pfizer or Moderna option. Novavax also is getting ready in case FDA urges a fall update, by manufacturing several additional formulas.
…

your ads here!

The Supreme Court is deciding whether women will face restrictions in getting a drug used in the most common method of abortion in the United States, while a lawsuit continues.

The justices are expected to issue an order on Wednesday in a fast-moving case from Texas in which abortion opponents are seeking to roll back Food and Drug Administration approval of the drug, mifepristone.

The drug first won FDA approval in 2000, and conditions on its use have been loosened in recent years, including making it available by mail in states that allow access.

The Biden administration and New York-based Danco Laboratories, the maker of the drug, want the nation’s highest court to reject limits on mifepristone’s use imposed by lower courts, at least as long as the legal case makes it way through the courts. They say women who want the drug and providers who dispense it will face chaos if limits on the drug take effect. Depending on what the justices decide, that could include requiring women to take a higher dosage of the drug than the FDA says is necessary.

Alliance Defending Freedom, representing anti-abortion doctors and medical groups in a challenge to the drug, is defending the rulings in calling on the Supreme Court to let the restrictions take effect now.

The legal fight over abortion comes less than a year after conservative justices reversed Roe v. Wade and allowed more than a dozen states to effectively ban abortion outright.

Even as the abortion landscape changed dramatically in several states, abortion opponents set their sights on medication abortions, which make up more than half of all abortions in the United States.

The abortion opponents filed suit in November in Amarillo, Texas. The legal challenge quickly reached the Supreme Court after a federal judge issued a ruling on April 7 that would revoke FDA approval of mifepristone, one of two drugs used in medication abortions.

Less than a week later, a federal appeals court modified the ruling so that mifepristone would remain available while the case continues, but with limits. The appeals court said that the drug can’t be mailed or dispensed as a generic and that patients who seek it need to make three in-person visits with a doctor, among other things.

The generic version of mifepristone makes up two-thirds of the supply in the United States, its manufacturer, Las Vegas-based GenBioPro Inc., wrote in a court filing that underscored the perils of allowing the restrictions to be put into effect.

The court also said the drug should only be approved through seven weeks of pregnancy for now, even though the FDA since 2016 has endorsed its use through 10 weeks of pregnancy.

Complicating the situation, a federal judge in Washington has ordered the FDA to preserve access to mifepristone under the current rules in 17 Democratic-led states and the District of Columbia that filed a separate lawsuit.

The Biden administration has said the rulings conflict and create an untenable situation for the FDA.

In an order issued last Friday by Justice Samuel Alito, the court put the restrictions on hold through Wednesday to give the court time to consider the emergency appeal.

If the justices aren’t inclined to block the ruling from taking effect for now, the Democratic administration and Danco have a fallback argument, asking the court to take up the challenge to mifepristone, hear arguments and decide the case by early summer.

The court only rarely takes such a step before at least one appeals court has thoroughly examined the legal issues involved.

The 5th U.S. Circuit Court of Appeals in New Orleans already has ordered an accelerated schedule for hearing the case, with arguments set for May 17.

Mifepristone has been available for use in medication abortions in the United States since the FDA granted approval in 2000. Since then, more than 5 million women have used it, along with another drug, misoprostol, to induce abortions.
…

your ads here!

A group of American plastic surgeons has been working in  Ukraine since the beginning of Russia’s invasion, helping  wounded soldiers and civilians recover from war injuries. Omelyan Oshchudlyak has the story. Camera: Yuriy Dankevych    
…

your ads here!

Virtual medicine, or medical extended reality, uses virtual reality headsets and imaging software to supplement conventional medical treatments. Practitioners from around the world shared best practices at a recent conference in Los Angeles. Mike O’Sullivan reports.
…

your ads here!

Nigeria’s National Agency for Food and Drug Administration and Control, NAFDAC, announced a provisional approval of the R21 vaccine during a media briefing on Monday.

The regulatory agency’s consent came days after Ghana approved the vaccine.

NAFDAC said the vaccine is 70 to 80 percent efficient in preventing the mosquito-borne disease and could protect millions of children.

The agency’s director general, Mojisola Adeyeye, spoke to journalists in Abuja.

“The vaccine is indicated for prevention of clinical malaria on children from five months to 36 months of age,” Adeyeye said.

NAFDAC did not say when the vaccine will be rolled out, but Adeyeye said Nigeria will conduct in-country clinical trials and pharmacovigilance study.

The WHO says some 600,000 people die of malaria every year, most of them in Africa, many of them young children.

Nigeria accounts for the highest numbers of cases and deaths from malaria globally. Health experts say the vaccine could be a game changer.

Kunle Olobayo is a lead researcher at the National Institute for Pharmaceutical Research and Development.

“A proactive, preemptive intervention will definitely be most useful especially in countries like Nigeria,” said Olobayo. “Many interventions and steps that have been taken to reduce transmission have not been very successful because of our level of development, poverty. So, it will definitely change the dynamics.

The WHO has yet to approve the vaccine. The WHO Nigeria malaria program head, Lynda Ozor, said authorities are still reviewing the vaccine’s safety and efficacy.

“The WHO is reviewing the R21 data, and it’s being supported by an independent global advisory group on immunization and malaria experts.,” said Ozor. “This group will advise the WHO on whether to recommend the R21 vaccines for use. It has to be approved by the WHO to compliment the rollout of the first vaccine.”

Last year, the WHO consented to the world’s first malaria vaccine, Mosquirix.

Olobayo said that, without donor support, African countries could struggle to acquire the vaccines.

“Vaccines in Nigeria historically tend to be dependent on donor funding,” said Olobayo. “I have a feeling there might be some substantial international funding to get these products widely used.”

Oxford University is working with the Serum Institute of India to produce up to 200 million doses of R21 every year.
…

your ads here!

Mozambique has asked the World Health Organization to supply an additional 2 million doses of a cholera vaccine as the country struggles to control a spreading outbreak. 

The head of the Department of National Health Surveillance at the Ministry of Health, Domingos Guihole, told VOA that the government awaits the WHO’s response to the cholera vaccine request, admitting difficulties due to the high global demand for vaccines.

“At this moment in Mozambique, the cholera situation is not good,” Guihole said. “It is not good because we have 10 provinces affected by cholera. We have 53 districts in the whole country, 45 of which have active cholera disease.”

The official said the intent is to vaccinate the population in high-risk areas, such as the northern province of Nampula and Zambezia in the central part of the country.

Both provinces were hit hard by Cyclone Freddy, which tore across Mozambique twice inside two weeks last month.

All five provinces impacted by Freddy on its first and second passes have witnessed cholera outbreaks.

In addition to the risk of cholera, the government is concerned about a potential increase in cases of other waterborne diseases such as dysentery. Malaria is a concern, too; both are among the leading causes of mortality in Mozambique.

“During almost seven months from October to April 16, we have notified 27,000 cases of cholera with 124 deaths, so the situation is not good,” said Guihole. “We have to say to all Mozambicans that we must follow the recommendations from the Ministry of Health related to the hygiene of water, hygiene of food, and even the collective hygiene as well.”

In many parts of Mozambique, health workers are struggling to treat infected citizens at clinics and hospitals that were badly damaged by Cyclone Freddy.

The record-breaking storm, which lasted for several weeks, killed dozens of people in Mozambique and Malawi and destroyed many roads and bridges in addition to hospitals.
…

your ads here!

Billionaire Elon Musk said on Monday he will launch an artificial intelligence (AI) platform that he calls “TruthGPT” to challenge the offerings from Microsoft and Google.

He criticized Microsoft-backed OpenAI, the firm behind chatbot sensation ChatGPT, of “training the AI to lie” and said OpenAI has now become a “closed source,” “for-profit” organization “closely allied with Microsoft.”

He also accused Larry Page, co-founder of Google, of not taking AI safety seriously.

“I’m going to start something which I call ‘TruthGPT’, or a maximum truth-seeking AI that tries to understand the nature of the universe,” Musk said in an interview with Fox News Channel’s Tucker Carlson aired on Monday.

He said TruthGPT “might be the best path to safety” that would be “unlikely to annihilate humans.”

“It’s simply starting late. But I will try to create a third option,” Musk said.

Musk, OpenAI, Microsoft and Page did not immediately respond to Reuters’ requests for comment.

Musk has been poaching AI researchers from Alphabet Inc’s Google to launch a startup to rival OpenAI, people familiar with the matter told Reuters.

Musk last month registered a firm named X.AI Corp, incorporated in Nevada, according to a state filing. The firm listed Musk as the sole director and Jared Birchall, the managing director of Musk’s family office, as a secretary.

‘Civilizational destruction’

The move came even after Musk and a group of artificial intelligence experts and industry executives called for a six-month pause in developing systems more powerful than OpenAI’s newly launched GPT-4, citing potential risks to society.

Musk also reiterated his warnings about AI during the interview with Carlson, saying “AI is more dangerous than, say, mismanaged aircraft design or production maintenance or bad car production” according to the excerpts.

“It has the potential of civilizational destruction,” he said.

He said, for example, that a super intelligent AI can write incredibly well and potentially manipulate public opinions.

He tweeted over the weekend that he had met with former U.S. President Barack Obama when he was president and told him that Washington needed to “encourage AI regulation.”

Musk co-founded OpenAI in 2015, but he stepped down from the company’s board in 2018. In 2019, he tweeted that he left OpenAI because he had to focus on Tesla and SpaceX.

He also tweeted at that time that other reasons for his departure from OpenAI were, “Tesla was competing for some of the same people as OpenAI & I didn’t agree with some of what OpenAI team wanted to do.”

Musk, CEO of Tesla and SpaceX, has also become CEO of Twitter, a social media platform he bought for $44 billion last year.

In the interview with Fox News, Musk said he recently valued Twitter at “less than half” of the acquisition price.

In January, Microsoft Corp announced a further multi-billion dollar investment in OpenAI, intensifying competition with rival Google and fueling the race to attract AI funding in Silicon Valley.
…

your ads here!

Kenya is using the launch of its first operational observation satellite to promote space education and science through space clubs in schools. Kenya launched an operational 3U nanosatellite April 15 aboard the SpaceX Falcon Force base in the U.S. Victoria Amunga reports from Nairobi, Kenya. Camera: Jimmy Makhulo
…

your ads here!

Scientists found coastal species of shellfish and anemones living and breeding on floating islands of garbage in the Pacific thousands of miles from home, a study revealed Monday. 

Environmentalists have for years been eyeing what they call the “Great Pacific Garbage Patch” — masses of plastic rubbish combining bottles, fishing nets and much more.

U.S. researchers who sampled rubbish from the northeastern Pacific between California and Hawaii said they found 37 kinds of invertebrates that originated from coastal areas, mostly from countries such as Japan on the other side of the ocean.

“The high seas are colonized by a diverse array of coastal species, which survive and reproduce in the open ocean,” they wrote in the study, published in Nature Ecology and Evolution.

“Coastal species persist now in the open ocean as a substantial component of a neopelagic [new, sea-dwelling] community sustained by the vast and expanding sea of plastic debris,” the study said.

More than two-thirds of the items examined had coastal species on them, including crustaceans, sea anemones and moss-like creatures called bryozoans.

Scientists had not often tracked creatures surviving dispersal across entire oceans. The researchers noted that in one rare event in 2012, debris from the previous year’s tsunami in Japan washed ashore in North America bearing living species.

Creatures can spread quickly by feeding on the layers of slime formed on floating plastics by bacteria and algae, the study said. Scientists must now investigate how these coastal colonists will fit into the ocean food chain.

“We found that coastal species are commonly observed on the same plastics as the native pelagic species [dwelling far out at sea], suggesting that these two communities are interacting with one another,” the study’s lead author Linsey Haram told AFP.

“These interactions could include competition for food and space as well as predation. More research is needed to understand whether the implications are positive or negative.” 

In a 2021 article, members of the same research team warned that the influx of invasive coastal species “might portend significant ecological shifts in the marine environment.”  

A study published in 2017 in the journal Science Advances calculated that if current production and waste-management trends continued, there would be 12 billion tons of plastic waste in landfills or the natural environment by 2050.

G-7 energy and environment ministers declared at the end of talks in Japan on Sunday their “ambition to reduce additional plastic pollution to zero by 2040.”

They said they hoped to draw up an “international legally binding instrument on plastic pollution” by the end of 2024. 
…

your ads here!

Two years ago, Paul’s teacher noticed that the 10-year-old boy could no longer see anything on the board at the front of the class.

An ophthalmologist confirmed that Paul was one of the soaring number of children worldwide with myopia, also known as nearsightedness, an eye condition projected to affect half of the world’s population by 2050.

But the ophthalmologist in the western French city of Nantes had some good news: specially designed glasses had just become available that could slow down the progression of Paul’s myopia.

“After a year, the results were quite positive because his eyesight seemed to have stabilized,” Paul’s mother Caroline Boudet told AFP.

Previous research has suggested that myopia progresses 60% slower in children wearing the “Miyosmart” glasses compared to normal prescription glasses.

A six-year clinical study also found that the disorder did not start speeding up again if the children stopped using the glasses.

Developed by Japan’s Hoya Corporation, the Miyosmart lenses, which also function as normal glasses to help the children see clearly, have been available in numerous European countries including France and the U.K. for around two years.

Eyewear firm EssilorLuxottica claims its own Stellest lenses reduce myopia’s progression by 67% when worn at least 12 hours a day.

The Italian French firm said the glasses could save more than one dioptre — the unit of measurement for optical power — over three years.

Myopia occurs when there is too much distance between the cornea and retina, making far-off objects appear blurry.

Both Miyosmart and Stellest glasses deploy hundreds of tiny lenses to counteract peripheral hyperopic defocus in which light falls behind the retina, causing the eyeball to get longer and making myopia worse.

The Miyosmart glasses are not available in the United States, however contact lenses that work on a similar principle from the California firm CooperVision have been approved by the U.S. Food and Drug Administration.

Research has suggested that the percentage of people affected by myopia worldwide could surge from 27% in 2010 to 52% by 2050.

Children with at least one nearsighted parent are more likely to develop the condition — however no one in Paul’s family is myopic.

Environmental rather than genetic causes are believed to be behind the explosion of cases.

Children spending more time indoors, being exposed to less natural light, and looking at nearby objects such as screens has likely brought about what has been dubbed “the myopia generation,” according to researchers.

Claude Speeg-Schatz, head of the French Society of Ophthalmology, said she was “quite amazed” by the new glasses slowing myopia’s progression.

“We have tried many things to avoid myopia, but this is the first time that we have a system which really works,” she said.

For recently diagnosed children, she first prescribes normal corrective glasses.

“If the myopia increases, then I automatically prescribe” the myopia control glasses, she said.

French ophthalmologist Jimmy Chammas said the glasses were “a real gain for children.”

“The myopia of those who wear these glasses deteriorates half as much as we would have expected — if at all,” he said.

One obstacle is that the glasses cost more for parents, with prices depending on the country.

Jean-Michel Lambert, head of Hoya Vision Care France, called for the glasses to be reimbursed by French health services.

“Each dioptre lost considerably increases the risk of future pathologies,” he said, adding that “if we slow down myopia, it will be one less cost for society.

If a prescription reads -2, that indicates two dioptres of nearsightedness.

Nearsightedness of -6 dioptres or more is called high myopia, which can increase the risk of serious eye damage such as retinal detachment, glaucoma or early onset cataracts.
…

your ads here!